Curve Biosciences announced it raised $17.7 Million in an initial filing from an offering of $20 Million

Company

Location

About

Curve Biosciences (“Curve”) is a company unlocking the potential of Chronic Epigenetics to bring precision to chronic disease care. Curve creates products that target the biological changes in tissues that result in the development and progression of chronic diseases. Curve’s Whole Body Tissue Atlas (WBTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies.